若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

EasySep™人FITC正选试剂盒II

对来源于外周血单个核细胞或其他单细胞悬液中标记 FITC 缀合抗体的人细胞进行免疫磁珠正选分离

产品号 #(选择产品)

产品号 #17662_C

免疫磁珠正选FITC偶联抗体标记的人细胞

产品优势

  • 快速、简单
  • 无需分离柱

产品组分包括

  • EasySep™人FITC正选试剂盒II(产品号 #17662)
    • EasySep™ FITC分选抗体混合物,1 mL
    • 抗人CD32 FcR阻断剂, 1 mL
    • EasySep™ Dextran RapidSpheres™磁珠,1 mL
    • RoboSep™ 一抗偶联物专用管(手动操作无需使用),1支
  • RoboSep™人FITC正选试剂盒II(产品号 #17662RF)
    • EasySep™ FITC分选抗体混合物,1 mL
    • 抗人CD32 FcR阻断剂,1mL 
    • EasySep™ Dextran RapidSpheres™磁珠,1 mL
    • RoboSep™ 一抗偶联物专用管(手动操作无需使用),1支
    • RoboSep™ 缓冲液(产品号 #20104)x 2
    • RoboSep™过滤枪头 (产品号 #20125)x 2
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品,请参阅《实验方案与技术文档》

总览

使用EasySep™人FITC正选试剂盒,通过免疫磁性正选法可从新鲜、冻存的人外周血单个核细胞(PBMCs)或其他单细胞悬液中分离经异硫氰酸荧光素(FITC)偶联抗体标记的高纯度人细胞。EasySep™技术已在超过20年的公开研究中得到广泛应用,结合单克隆抗体特异性与无柱磁系统简便性。在此正选步骤中,目标细胞与能够识别FITC的和磁珠的抗体复合物结合。本试剂盒还含有抗人Fc受体阻断剂,以防止非特异性结合。标记细胞使用EasySep™磁体分离后,未标记细胞被去除,FITC+细胞留在试管中。分离后的细胞可立即用于流式细胞术、细胞培养或基于细胞的分析。

了解更多EasySep™免疫磁性技术或RoboSep™自动化系统。

磁极兼容性
• EasySep™磁极(产品号 #18000)
• “The Big Easy” EasySep™磁极(产品号 #18001)
• EasyEights™ EasySep™磁极(产品号 #18103)
• RoboSep™-S(产品号 #21000)
 
分类
细胞分选试剂盒
 
细胞类型
B 细胞,树突状细胞(DCs),粒细胞及其亚群,造血干/祖细胞,巨噬细胞,骨髓基质细胞,间充质干/祖细胞,单核细胞,单个核细胞,髓系细胞,NK 细胞,其他物种,血浆,T 细胞
 
种属

 
样本来源
白膜层,脐带血,白细胞单采术样本,其他物种,PBMC
 
分选方法
正选
 
应用
细胞分选
 
品牌
EasySep,RoboSep
 
研究领域
免疫
 

Data Figures

Starting with human PBMCs, the purities of the start and final isolated fractions in the above example are 6.7% and 91.0%, respectively, using a FITC-conjugated anti-human CD19 antibody and EasySep™ Human FITC Positive Selection Kit II.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17662
Lot #
All
Language
English
Catalog #
17662RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17662
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17662
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17662
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17662RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17662RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17662RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
17662RF
Lot #
All
Language
English

Resources and Publications

Educational Materials (7)

Publications (1)

Conditional CRISPR-mediated deletion of Lyn kinase enhances differentiation and function of iPSC-derived megakaryocytes. A. J. Moroi and P. J. Newman Journal of thrombosis and haemostasis : JTH 2022 jan

Abstract

BACKGROUND Thrombocytopenia leading to life-threatening excessive bleeding can be treated by platelet transfusion. Currently, such treatments are totally dependent on donor-derived platelets. To support future applications in the use of in vitro-derived platelets, we sought to identify genes whose manipulation might improve the efficiency of megakaryocyte production and resulting hemostatic effectiveness. Disruption of Lyn kinase has previously been shown to improve cell survival, megakaryocyte ploidy and TPO-mediated activation in mice, but its role in human megakaryocytes and platelets has not been examined. METHODS To analyze the role of Lyn at defined differentiation stages during human megakaryocyte differentiation, conditional Lyn-deficient cells were generated using CRISPR/Cas9 technology in iPS cells. The efficiency of Lyn-deficient megakaryocytes to differentiate and become activated in response to a range of platelet agonists was analyzed in iPSC-derived megakaryocytes. RESULTS Temporally controlled deletion of Lyn improved the in vitro differentiation of hematopoietic progenitor cells into mature megakaryocytes, as measured by the rate and extent of appearance of CD41+ CD42+ cells. Lyn-deficient megakaryocytes also demonstrated improved hemostatic effectiveness, as reported by their ability to mediate clot formation in rotational thromboelastometry. Finally, Lyn-deficient megakaryocytes produced increased numbers of platelet-like particles (PLP) in vitro. CONCLUSIONS Conditional deletion of Lyn kinase increases the hemostatic effectiveness of megakaryocytes and their progeny as well as improving their yield. Adoption of this system during generation of in vitro-derived platelets may contribute to both their efficiency of production and their ability to support hemostasis.

更多信息

更多信息
物种 人类
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源 PBMC, 其它细胞系, 白细胞单采术样本, 白膜层, 脐带血
Selection Method Positive
Legal Statement: Users of this kit should ensure that they are entitled to use the antibody of interest. STEMCELL Technologies Inc. is not responsible for patent infringements or violations that may occur when using this product. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.

在线联系